TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05573295

Intervention type: OTHER
Intervention: Diagnostic Test: Willems method
Description: Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.

Intervention type: OTHER
Intervention: Diagnostic Test: Cameriere method
Description: Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.

Intervention type: OTHER
Intervention: Diagnostic Test: Cameriere method
Description: Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.

Intervention type: OTHER
Intervention: Diagnostic Test: London Atlas method
Description: The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.

Intervention type: OTHER
Intervention: Diagnostic Test: London Atlas method
Description: The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
Study: NCT05827302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Gauge AI-Based Wearable Device - Model: Phoenix
Description: Wearable device
Study: NCT05798507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given PO
Study: NCT04975763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil Foods
Description: Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Palm Oil Foods
Description: Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
Study: NCT05910385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: tubal ligation by laparoscopy or vnotes technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vnotes
Description: tubal ligation by laparoscopy or vnotes technique
Study: NCT05298605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith in Action! Church-based Navigation Model
Description: Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
Study: NCT06207110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues
Description: ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues +
Description: ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
Study: NCT05194176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
Study: NCT06003725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Adolescent Substance Use Treatment
Description: The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
Study: NCT05501002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eShunt® Implant
Description: The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
Study: NCT03953768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS)
Description: Implantation with vagal nerve stimulator for epilepsy
Study: NCT05035979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BaidI Quzhi granule
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BaidI Quzhi granule
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ju Yin cream
Description: Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ju Yin cream
Description: Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baidi Quzhi placebo granule
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baidi Quzhi placebo granule
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ju Yin placebo cream
Description: Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ju Yin placebo cream
Description: Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
Study: NCT04978038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA- COVID-19
Description: Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
Study: NCT05379829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered 3 doses s.c. Q4W.
Study: NCT04819685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KANG FU PEN
Description: FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
Study: NCT05038410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym®
Description: Wobenzym®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study: NCT05791097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of pembrolizumab will be administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle
Study: NCT05098444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral psychotherapy
Description: Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
Study: NCT05864235

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Support (GS)
Description: Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
Study: NCT05791097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle
Study: NCT05864235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Support (GS)
Description: Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching for Context-specific Peer Support (CCPS)
Description: Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
Study: NCT06102824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Organoid-guided treatment
Description: The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000-1250mg/m2, PO, bid, days1-14, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 800-1200mg/m2, IV, days 1, 8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 20-35mg/m2, IV, days 1 and 8, q3w
Study: NCT05791097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle
Study: NCT04798833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Newborn Care Kit (iNCK)
Description: Contents of the integrated newborn care kit:~* Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~* 3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~* 4% CHX solution (15 mL)~* Sunflower oil emollient (50 mL)~* Temperature monitoring strip or sticker~* Fleece blanket for the newborn~* Click to heat warmer~* Pictorial guide that illustrates how and when to use each kit component~* Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit
Study: NCT05174975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Positive Psychological Intervention
Description: The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
Study: NCT05586867

Intervention type: PROCEDURE
Intervention: Blood test
Description: 15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
Study: NCT05569785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Therapy
Description: 4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only.
Study: NCT04856319

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dental implant placement
Description: Insertion of not more than two dental implants at the same area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: Insertion of not more than two dental implants at the same area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis
Description: Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
Study: NCT05279417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450 50 mg oral tablet BID
Description: Oral, small molecule MK2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg to 25 mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg to 25 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 15 mg to 25 mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450 20 mg oral tablet BID
Description: Oral, small molecule MK2 inhibitor
Study: NCT05567224

Intervention type: OTHER
Intervention: Access to primary care services
Description: Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
Study: NCT05619445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Liquid Egg
Description: Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Egg Substitute
Description: Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
Study: NCT06102824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m2, IV, days 1 and 8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracycline
Description: Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utidelone
Description: 30mg/m2, IV, once per day on days 1-5, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: 5.4mg/kg, IV, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan
Description: 10mg/kg, IV, days 1 and 8, q3w
Study: NCT05875623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MALPIP criteria
Description: In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients